#heateor_sss_mastodon_popup_bg,#heateor_sss_popup_bg{--wpr-bg-9b170f74-f044-495f-b4b6-265a96f3b718: url('https://www.delveinsight.com/blog/blog/wp-content/plugins/sassy-social-share/images/transparent_bg.png');}.rll-youtube-player .play{--wpr-bg-87c92c46-cb51-4b9c-b591-2109573e5141: url('https://www.delveinsight.com/blog/wp-content/plugins/wp-rocket/assets/img/youtube.png');}

0

Home Blog Tag Acerta pharma

Acerta Pharma

Aug 15, 2019

EU approval for Imbruvica; Pharming licenses orphan drug

EU recommends the use of Imbruvica for two new indications The Janssen Pharmaceutical has received the approval for its drug Imbruvica (ibrutinib) from the European Commission (EC). Ibrutinib is a first-in-class targeted therapy, which inhibits the function of Bruton's tyrosine kinase (BTK). Jointly developed an...

Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies

Snippets - A Small piece of News or Article

Jul 04, 2025

A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

Articles

Jun 10, 2025

ADCs in Lung Cancer Treatment: ENHERTU’s Rise, HER3 & TROP-2 Challenges, and What’s Next in the Pipeline

Articles

May 09, 2025

LEQEMBI: A New Hope for Alzheimer’s Disease Patients

Articles